3076 related articles for article (PubMed ID: 22085203)
1. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
[TBL] [Abstract][Full Text] [Related]
3. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
[TBL] [Abstract][Full Text] [Related]
4. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence.
Corcoran NM; Hong MK; Casey RG; Hurtado-Coll A; Peters J; Harewood L; Goldenberg SL; Hovens CM; Costello AJ; Gleave ME
BJU Int; 2011 Oct; 108(8 Pt 2):E202-10. PubMed ID: 21443656
[TBL] [Abstract][Full Text] [Related]
5. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
6. Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours.
Corcoran NM; Hovens CM; Hong MK; Pedersen J; Casey RG; Connolly S; Peters J; Harewood L; Gleave ME; Goldenberg SL; Costello AJ
BJU Int; 2012 Mar; 109(5):660-4. PubMed ID: 21895937
[TBL] [Abstract][Full Text] [Related]
7. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
8. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
9. Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy.
Thomas C; Pfirrmann K; Pieles F; Bogumil A; Gillitzer R; Wiesner C; Thüroff JW; Melchior SW
BJU Int; 2012 Jan; 109(2):214-9. PubMed ID: 21592293
[TBL] [Abstract][Full Text] [Related]
10. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.
Tilki D; Schlenker B; John M; Buchner A; Stanislaus P; Gratzke C; Karl A; Tan GY; Ergün S; Tewari AK; Stief CG; Seitz M; Reich O
Urol Oncol; 2011; 29(5):508-14. PubMed ID: 19837614
[TBL] [Abstract][Full Text] [Related]
11. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
12. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
[TBL] [Abstract][Full Text] [Related]
13. Should we replace the Gleason score with the amount of high-grade prostate cancer?
Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
[TBL] [Abstract][Full Text] [Related]
14. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
King CR; McNeal JE; Gill H; Presti JC
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152
[TBL] [Abstract][Full Text] [Related]
15. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer.
Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS
BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303
[TBL] [Abstract][Full Text] [Related]
16. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
17. Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.
Huang JG; Pedersen J; Hong MK; Harewood LM; Peters J; Costello AJ; Hovens CM; Corcoran NM
BJU Int; 2013 May; 111(6):921-7. PubMed ID: 23350712
[TBL] [Abstract][Full Text] [Related]
18. Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer.
Krane LS; Menon M; Kaul SA; Siddiqui SA; Wambi C; Peabody JO; Agarwal PK
Urol Oncol; 2011; 29(4):372-7. PubMed ID: 19576796
[TBL] [Abstract][Full Text] [Related]
19. Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen, and Gleason score to predict prostate cancer recurrence after radical prostatectomy.
Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
Eur Urol; 2004 Nov; 46(5):571-8. PubMed ID: 15474265
[TBL] [Abstract][Full Text] [Related]
20. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
